Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01841021 | Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 | terminated | N/A | 1 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 19, 2017 | clinicaltrials |
| NCT01695330 | Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens | terminated | Phase 2 | 5 | OncotherapeuticsINDUSTRY | 1 | Jan 16, 2017 | clinicaltrials |
| NCT01032148 | Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma | terminated | Phase 1 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT01637090 | Everolimus in Treating Cutaneous T-cell Lymphoma(CTCL) | terminated | Phase 2 | 3 | Adam LernerOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT01947309 | Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide) | terminated | — | 176 | CelgeneINDUSTRY | 1 | Jan 12, 2017 | clinicaltrials |
| NCT02439138 | Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia | terminated | Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT02086591 | A Phase II Study of Doxycycline in Relapsed NHL | terminated | Phase 2 | 7 | University of RochesterOTHER | 1 | Dec 22, 2016 | clinicaltrials |
| NCT01944982 | Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma(HNJ-NKAES-2012) | terminated | Phase 1 / Phase 2 | 7 | Hospital Infantil Universitario Niño Jesús, Madrid, SpainOTHER | 1 | Dec 20, 2016 | clinicaltrials |
| NCT01555853 | Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma | terminated | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Dec 6, 2016 | clinicaltrials |
| NCT01908413 | Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma | terminated | Phase 1 | 23 | Curis, Inc.INDUSTRY | 1 | Dec 1, 2016 | clinicaltrials |
| NCT00978432 | Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | terminated | Phase 2 | 50 | Anne Beaven, MDOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT01745354 | Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT) | terminated | Phase 1 | 6 | Robert LowskyOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT01609036 | An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma | terminated | — | 3 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01724294 | An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma | terminated | — | 113 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02020941 | Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy | terminated | Phase 2 | 10 | Attaya SuvannasankhaOTHER | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01541072 | Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation(PALM2) | terminated | N/A | 34 | Centre Leon BerardOTHER | 1 | Nov 1, 2016 | clinicaltrials |
| NCT01186458 | Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma | terminated | Phase 2 | 4 | Hoosier Cancer Research NetworkOTHER | 1 | Oct 24, 2016 | clinicaltrials |
| NCT01144403 | A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma. | terminated | Phase 2 | 8 | Hoffmann-La RocheINDUSTRY | 1 | Oct 18, 2016 | clinicaltrials |
| NCT01699581 | Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant | terminated | Phase 2 | 35 | Greg MonohanOTHER | 1 | Oct 18, 2016 | clinicaltrials |
| NCT00788606 | R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma | terminated | Phase 2 | 7 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT01188915 | Personalised Program for Women Treated for Hodgkin Disease(PROPER) | terminated | N/A | 51 | Institut Paoli-CalmettesOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT00912899 | A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 12 | Cougar Biotechnology, Inc.INDUSTRY | 1 | Oct 7, 2016 | clinicaltrials |
| NCT01423760 | Common Safety Follow-up Trial of Tecemotide (L-BLP25) | terminated | N/A | 27 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Oct 6, 2016 | clinicaltrials |
| NCT00278265 | Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia | terminated | Phase 2 | 12 | German CLL Study GroupOTHER | 1 | Oct 3, 2016 | clinicaltrials |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | terminated | Phase 1 | 155 | Mirna Therapeutics, Inc.INDUSTRY | 2 | Sep 27, 2016 | clinicaltrials |
| NCT02573935 | Clarithromycin in Multiple Myeloma Induction Therapy(CLAIM) | terminated | Phase 2 | 58 | Henrik GregersenOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT00920153 | Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma | terminated | Phase 3 | 442 | French Innovative Leukemia OrganisationOTHER | 1 | Sep 16, 2016 | clinicaltrials |
| NCT01985477 | Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2016 | clinicaltrials |
| NCT01121757 | Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma | terminated | Phase 2 | 11 | Duke UniversityOTHER | 1 | Sep 12, 2016 | clinicaltrials |
| NCT00984828 | Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients | terminated | Phase 2 / Phase 3 | 23 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 8, 2016 | clinicaltrials |
| NCT02808091 | Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma(Gifox-B) | terminated | Phase 2 | 7 | National Cancer Centre, SingaporeOTHER | 1 | Sep 5, 2016 | clinicaltrials |
| NCT00195897 | Early Assessment of Anthracycline-induced Cardiotoxicity (CARDIOTOX) | terminated | — | 6 | Centre Henri BecquerelOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT00879528 | Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory | terminated | — | 264 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 17, 2016 | clinicaltrials |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2016 | clinicaltrials |
| NCT01078974 | Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia | terminated | Phase 1 | 7 | Steven P. Treon, MD, PhDOTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT01096810 | Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma | terminated | Phase 2 | 20 | Jagannath, Sundar, M.D.INDIV | 1 | Jul 22, 2016 | clinicaltrials |
| NCT02739594 | Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma(COMPARE) | terminated | Phase 3 | 89 | Hoffmann-La RocheINDUSTRY | 1 | Jul 22, 2016 | clinicaltrials |
| NCT02046928 | Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 2 | 5 | Ångstrom PharmaceuticalsINDUSTRY | 1 | Jul 13, 2016 | clinicaltrials |
| NCT00983346 | Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients | terminated | Phase 2 | 17 | University of UtahOTHER | 1 | Jul 11, 2016 | clinicaltrials |
| NCT00004239 | 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment | terminated | Phase 1 | 10 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 4, 2016 | clinicaltrials |
| NCT01144754 | Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT | terminated | — | 1 | Stanford UniversityOTHER | 1 | Jul 1, 2016 | clinicaltrials |
| NCT01556828 | Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing | terminated | — | 70 | Stanford UniversityOTHER | 1 | Jun 24, 2016 | clinicaltrials |
| NCT02273856 | Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)(NADIR) | terminated | — | 25 | Astellas Pharma International B.V.INDUSTRY | 7 | Jun 21, 2016 | clinicaltrials |
| NCT01536067 | Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia | terminated | Phase 2 | 3 | Roswell Park Cancer InstituteOTHER | 1 | Jun 10, 2016 | clinicaltrials |
| NCT02080416 | Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors | terminated | Early Phase 1 | 1 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 10, 2016 | clinicaltrials |
| NCT01658904 | Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2016 | clinicaltrials |
| NCT01182233 | Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic Stem Cell Transplantation | terminated | Phase 1 | 4 | University of RochesterOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT00512460 | RTA 744 Injection in Patients With Leptomeningeal Disease | terminated | Phase 1 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | May 16, 2016 | clinicaltrials |
| NCT01807286 | Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis | terminated | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | May 13, 2016 | clinicaltrials |
Data updated 24 days agoSource updated Jan 19, 2017source: clinicaltrials